{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:35Z","timestamp":1791388115887,"version":"4.3.3"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1996,9]]},"DOI":"10.1212\/wnl.47.3.674","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:23:00Z","timestamp":1336915380000},"page":"674-677","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":170,"title":["Complications of intravenous immune globulin treatment in neurologic disease"],"prefix":"10.1212","volume":"47","author":[{"suffix":"III","given":"Thomas H.","family":"Brannagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Nagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis P.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","first-page":"3","volume":"264","year":"1990","unstructured":"National Institute of Health Consensus Conference: Intravenous immune globulin prevention and treatment of disease. JAMA 1990;264:3189-3193.","journal-title":"JAMA"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350703"},{"key":"e_1_3_1_4_2","first-page":"1","volume":"50","year":"1993","unstructured":"Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135-136.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307013290101"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201023260101"},{"key":"e_1_3_1_7_2","first-page":"8","volume":"36","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.1_Part_1.8"},{"key":"e_1_3_1_9_2","first-page":"1","volume":"146","year":"1986","unstructured":"Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High dose IVIg in the management of MG. Arch Intern Med 1986;146:1365-1368.","journal-title":"Arch Intern Med"},{"key":"e_1_3_1_10_2","first-page":"1","volume":"49","year":"1992","unstructured":"Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of IVIg in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-1236.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_11_2","first-page":"2","volume":"33","year":"1993","unstructured":"Chaudhrey V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-242.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_12_2","first-page":"2","volume":"40","year":"1990","unstructured":"Cook D, Dalakas MC, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.","journal-title":"Neurology"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90065-6"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.1.1"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.1.1"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.1.1"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90483-9"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00544.x"},{"key":"e_1_3_1_19_2","first-page":"2","volume":"37","year":"1992","unstructured":"Phillips AO. Renal failure and intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:217.","journal-title":"Clin Nephrol"},{"key":"e_1_3_1_20_2","first-page":"8","volume":"36","year":"1991","unstructured":"Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-86.","journal-title":"Clin Nephrol"},{"key":"e_1_3_1_21_2","first-page":"1","volume":"50","year":"1993","unstructured":"Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207023270101"},{"key":"e_1_3_1_23_2","first-page":"2","volume":"37","year":"1992","unstructured":"Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:216-217.","journal-title":"Clin Nephrol"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407073310101"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407073310101"},{"key":"e_1_3_1_26_2","first-page":"2","volume":"44","year":"1994","unstructured":"Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.","journal-title":"Neurology"},{"key":"e_1_3_1_27_2","first-page":"2","volume":"42","year":"1992","unstructured":"Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.","journal-title":"Neurology"},{"key":"e_1_3_1_28_2","first-page":"2","volume":"121","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-262.","journal-title":"Ann Intern Med"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.1.1"},{"key":"e_1_3_1_30_2","first-page":"9","volume":"55","year":"1992","unstructured":"Casteels-van Daele M, Wijndaele L, Brock P, Kruger M, Gillis P. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1992;55:980-981.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_31_2","first-page":"2","volume":"326","year":"1991","unstructured":"Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin [letter]. N Engl J Med 1991;326:270-271.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360703"},{"key":"e_1_3_1_33_2","first-page":"1","volume":"296","year":"1988","unstructured":"Majer RV, Green PJ. Neutropenia caused by intravenous immunoglobulin [letter]. BMJ 1988;296:1262.","journal-title":"BMJ"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80589-X"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.295.6589.1"},{"key":"e_1_3_1_36_2","first-page":"1","year":"1987","unstructured":"Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion [letter]. Lancet 1987;i:1436.","journal-title":"Lancet"},{"key":"e_1_3_1_37_2","first-page":"2","volume":"9","year":"1993","unstructured":"Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.","journal-title":"Drug Saf"},{"key":"e_1_3_1_38_2","first-page":"3","volume":"78","year":"1993","unstructured":"Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica (Suppl) 1993;78:35-40.","journal-title":"Haematologica (Suppl)"},{"key":"e_1_3_1_39_2","first-page":"8","volume":"135","year":"1996","unstructured":"Lisak RP. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996;135:85-88.","journal-title":"J Neurol Sci"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90483-9"},{"key":"e_1_3_1_41_2","first-page":"4","volume":"150","year":"1989","unstructured":"Nicholls MD, Cummins JC, Davies VJ, Greenwood JK. Haemolysis induced by intravenously administered immunoglobulin. Med J Aust 1989;150:404-406.","journal-title":"Med J Aust"},{"key":"e_1_3_1_42_2","first-page":"9","volume":"319","year":"1988","unstructured":"Cooperative Group for the Study of Immunoglobulin in chronic lymphocytic leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988;319:902-907.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_43_2","first-page":"7","volume":"325","year":"1991","unstructured":"National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Eng J Med 1991;325:73-80.","journal-title":"N Eng J Med"},{"key":"e_1_3_1_44_2","first-page":"2","volume":"112","year":"1990","unstructured":"Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.","journal-title":"Ann Intern Med"},{"key":"e_1_3_1_45_2","first-page":"3","volume":"19","year":"1996","unstructured":"Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996;19:388-391.","journal-title":"Muscle Nerve"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1159\/000187272"},{"key":"e_1_3_1_47_2","unstructured":"Ropper AH Wijdicks EFM Truax BT. Guillain-Barre syndrome. Philadelphia: F.A. Davis 1991."},{"key":"e_1_3_1_48_2","first-page":"4","volume":"81","year":"1986","unstructured":"Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteriods for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med 1986;81:443-446.","journal-title":"Am J Med"},{"key":"e_1_3_1_49_2","unstructured":"Koffman B Dalakas MC. Effect of high-dose intravenous immunoglobulin (IVIg) on hematological and serum chemistry profiles in the treatment of patients with neuromuscular diseases [abstract]. Neurology 1995;45(suppl 4):A235."},{"key":"e_1_3_1_50_2","first-page":"1","volume":"81","year":"1993","unstructured":"Horowitz B, Prince AM, Horowitz MS, Watklevicz C. Viral safety of solvent-detergent treated blood products. In: Brown F, ed: Virological safety aspects of plasma derivatives. Dev Biol Stand. Basel: Karger, 1993;81:147-161.","journal-title":"Basel: Karger,"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501053320101"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.47.3.674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:14:10Z","timestamp":1711534450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.47.3.674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,9]]}},"alternative-id":["10.1212\/WNL.47.3.674"],"URL":"https:\/\/doi.org\/10.1212\/wnl.47.3.674","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,9]]}}}